Skip to main content

New line of attack against advanced prostate cancer in a study led by a Catalan scientist

12 Dec 17




Press and Communications Officer
Tel.+34 93 40 37255

The Catalan Media Corporation, La Razón and have highlighted a study conducted by Xavier Salvatella, ICREA researcher at IRB Barcelona, and published in the journal Structure early in December. In this work, he proposes various ways to tackle prostate cancer and focuses on the androgen receptor protein, which tumour cells need to survive and proliferate. 

Link to CCMA

Link to La Razón

Link to

About IRB Barcelona

Created in 2005 by the Generalitat de Catalunya (Government of Catalonia) and University of Barcelona, IRB Barcelona is a Severo Ochoa Centre of Excellence, a seal that was awarded in 2011. The institute is devoted to conducting research of excellence in biomedicine and to transferring results to clinical practice, thus improving people’s quality of life, while simultaneously promoting the training of outstanding researchers, technology transfer, and public communication of science. Its 27 laboratories and eight core facilities address basic questions in biology and are orientated to diseases such as cancer, metastasis, Alzheimer’s, diabetes, and rare conditions. IRB Barcelona is an international centre that hosts 400 employees and more than 30 nationalities. It is located in the Barcelona Science Park. IRB Barcelona is a CERCA center, and a member of the Barcelona Institute of Science and Technology (BIST).